Bedaquiline: An In-Depth Exploration into Its Antitubercular Significance

Year : 2025 | Volume : 12 | Issue : 02 | Page : 06 14
    By

    Subha Deepa,

  • D. Visagaperumal,

  • Vineeth Chandy,

  1. Student, Department of Pharmaceutical Chemistry, T. John College of Pharmacy, Bengaluru, Karnataka, India
  2. HOD, Department of Pharmaceutical Chemistry, T. John College of Pharmacy, Bengaluru, Karnataka, India
  3. Principal, T. John College of Pharmacy, Bangalore, Karnataka, India

Abstract

Tuberculosis is still a leading infectious disease and a major threat to public health. Although there has been a slow decrease in the incidence over years, its “hard to kill nature” is responsible of about 2 million deaths in HIV infected individuals annually. Bedaquiline, a Diaryl-Quinoline drug was fast-track approved as an orphan drug to combat drug resistance. It shows potent activity against Mycobacterium tuberculosis by interfering with the production of ATP. The main mechanism of action of Bedaquiline involves binding to the F0 domain of the ATP synthase complex and prevents its function, thereby inhibiting the oxidative phosphorylation of the cell ultimately inhibition of ATP generation. In an era of growing resistance and considering the suboptimal efficacy and toxicity of current MDR-TB regimens, Bedaquiline represents a significant contribution to the existing resources of anti-TB drugs, particularly in endemic areas of the world. This paper aims to provide an overview of the drug Bedaquiline, its mechanism of action, microbiology, pharmacokinetics and pharmacodynamics, the chemistry and SAR and design strategies for novel analogues.

Keywords: Tuberculosis, bedaquiline, ATP synthase, diarylquinolines, World Health Organization

[This article belongs to Research & Reviews: A Journal of Drug Design & Discovery ]

How to cite this article:
Subha Deepa, D. Visagaperumal, Vineeth Chandy. Bedaquiline: An In-Depth Exploration into Its Antitubercular Significance. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(02):06-14.
How to cite this URL:
Subha Deepa, D. Visagaperumal, Vineeth Chandy. Bedaquiline: An In-Depth Exploration into Its Antitubercular Significance. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(02):06-14. Available from: https://journals.stmjournals.com/rrjoddd/article=2025/view=216517


References

  1. World Health Organization. Global Tuberculosis Report 2025 [Internet]. 2025 [cited 2025 May 31]. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
  2. Tang YW, Sussman M, Liu D, Poxton IR, Schwartzman JD. Molecular Medical Microbiology–The Expanding Concept. In: Molecular Medical Microbiology. 2015 Jan 1. pp. 1–4. Academic Press. Available from: https://doi.org/10.1016/B978-0-12-397169-2.00001-9
  3. Hu Y, Pertinez H, Liu Y, Davies G, Coates A. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure. J Antimicrob Chemother. 2019 Jun;74(6):1627–33. doi: 10.1093/jac/dkz052
  4. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull. 2005;73–74(1):17–24. doi: 10.1093/bmb/ldh047
  5. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep 1;5(9):a017863.
  6. Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014070. doi: 10.4084/MJHID.2014.070
  7. Huitric E, Verhasselt P, Andries K, Hoffner SE. In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor. Antimicrob Agents Chemother. 2007;51:2327–9. doi: 10.1128/aac.00181-07
  8. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005 Jan 14;307(5707):223–7. doi: 10.1126/science.1106753
  9. Vocat A, Hartkoorn RC, Lechartier B, Zhang M, Dhar N, Cole ST, et al. Bioluminescence for Assessing Drug Potency against Nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:6361–7. doi: 10.1128/aac.00528-15
  10. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 2008 Sep 12;283(37):25273–80.
  11. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271–6. doi: 10.1128/aac.06126-11
  12. Bald D, Villellas C, Lu P, Koul A. Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery. MBio. 2017;8(2):e00272–17. doi: 10.1128/mBio.00272-17
  13. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol. 2003;48(1):77–84.
  14. Tran SL, Cook GM. The F1Fo-ATP synthase of Mycobacterium smegmatis is essential for growth. J Bacteriol. 2005;187(14):5023–8.
  15. Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(5):2491–503.
  16. Nakamoto RK, Scanlon JAB, Al-Shawi MK. The rotary mechanism of the ATP synthase. Arch Biochem Biophys. 2008;476(1):43–50.
  17. Mitome N, Ono S, Sato H, Suzuki T, Sone N, Yoshida M. Essential arginine residue of the Fo-a subunit in FoF1-ATP synthase prevents proton shortcut without c-ring rotation. Biochem J. 2010;430(1):171–7.
  18. Diez M, Zimmermann B, Börsch M, König M, Schweinberger E, Steigmiller S, et al. Proton-powered subunit rotation in single membrane-bound F0F1-ATP synthase. Nat Struct Mol Biol. 2004;11(2):135–41.
  19. Kamariah N, Huber RG, Nartey W, Bhushan S, Bond PJ, Grüber G. Structure and subunit arrangement of mycobacterial F1FO ATP synthase and novel features of the unique mycobacterial subunit δ. J Struct Biol. 2019;207(2):199–208.
  20. Preiss L, Langer JD, Yildiz Ö, Eckhardt-Strelau L, Guillemont JE, Koul A, et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv. 2015;1(4):e1500106.
  21. Guo H, Suzuki T, Rubinstein JL. Structure of a bacterial ATP synthase. Elife. 2019;8:e43128.
  22. Biuković G, Basak S, Manimekalai MSS, Rishikesan S, Roessle M, Dick T, et al. Variations of subunit ε of the Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207. Antimicrob Agents Chemother. 2013;57(1):168–76.
  23. Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis. 2015 Jul;6(4):170–84.
  24. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863.
  25. Bedaquiline [Internet]. Available from: https://go.drugbank.com/drugs/DB08903 [cited 2023 Aug 28].
  26. National Center for Biotechnology Information. PubChem Compound Summary for CID 5388906, Bedaquiline [Internet]. 2023 [cited 2023 Dec 15]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Bedaquiline
  27. O’Neil MJ, editor. The Merck Index – An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry; 2013. p. 178–9.
  28. Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014;48(1):107–15.
  29. He C, Preiss L, Wang B, Fu L, Wen H, Zhang X, et al. Structural simplification of bedaquiline: the discovery of 3-(4-(N,N-dimethylaminomethyl)phenyl)quinoline-derived antitubercular lead compounds. ChemMedChem. 2017;12(2):106–19.
  30. Barbaro L, Nagalingam G, Triccas JA, Tan L, West NP, Priebbenow DL, et al. Discovery of anti-tubercular analogues of bedaquiline with modified A-, B- and C-ring subunits. ChemMedChem. 2023;18(1):e202200533.
Regular Issue Subscription Original Research
Volume 12
Issue 02
Received 21/12/2024
Accepted 22/02/2025
Published 29/03/2025
Publication Time 98 Days
116


My IP

PlumX Metrics